Table 8Proportions of patients with serious adverse events across all trials

Fingolimod 1.25 mg once daily
N=943
Fingolimod 0.5 mg once daily
N=854
Interferon beta-1a
N=431
Placebo
N=511
Cardiac disorders (%)2.41.200.2
Nervous system disorders (%)1.91.40.71.0
Infections and infestations (%)1.90.91.41.6

From: Results

Cover of Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod
Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet].
McDonagh M.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.